[図1]

配列番号１：抗ＨＥＲ２抗体重鎖のアミノ酸配列

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTR
YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[図2]

配列番号２：抗ＨＥＲ２抗体軽鎖のアミノ酸配列

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP
SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIF
PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS
TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[図3]

配列番号３：抗ＨＥＲ３抗体の重鎖のアミノ酸配列

QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNY
NPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSSA
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[図4]

配列番号４：抗ＨＥＲ３抗体の軽鎖のアミノ酸配列

DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWAST
RESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIKRTVAA
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[図5]

配列番号５：抗ＴＲＯＰ２抗体重鎖のアミノ酸配列

MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQA
PGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARS
GFGSSYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK
RVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

シグナル配列（１－１９）、可変領域（２０－１４０）、定常領域（１４１－４７０）

[図6]

配列番号６：抗ＴＲＯＰ２抗体軽鎖のアミノ酸配列

MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQK
PGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTF
GQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

シグナル配列（１－２０）、可変領域（２１－１２９）、定常領域（１３０－２３４）

[図7]

配列番号７：抗Ｂ７－Ｈ３抗体重鎖のアミノ酸配列

MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYVMHWVRQA
PGQGLEWMGYINPYNDDVKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARW
GYYGSPLYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD
KRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

シグナル配列（１－１９）、可変領域（２０－１４１）、定常領域（１４２－４７１）

[図8]

配列番号８：抗Ｂ７－Ｈ３抗体軽鎖のアミノ酸配列

MVLQTQVFISLLLWISGAYGEIVLTQSPATLSLSPGERATLSCRASSRLIYMHWYQQKP
GQAPRPLIYATSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWNSNPPTFG
QGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

シグナル配列（１－２０）、可変領域（２１－１２８）、定常領域（１２９－２３３）

[図9]

配列番号９：抗ＧＰＲ２０抗体重鎖のアミノ酸配列

MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYISWIRQA
PGQGLKYMGFINPGSGHTNYNEKFKGRVTITADKSSSTATMELSSLRSEDTAVYYCARG
AGGFLRIITKFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV
DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

シグナル配列（１－１９）、可変領域（２０－１４２）、定常領域（１４３－４７２）

[図10]

配列番号１０：抗ＧＰＲ２０抗体軽鎖のアミノ酸配列

MVLQTQVFISLLLWISGAYGDTQLTQSPSSLSASVGDRVTITCRASKSVSTYIHWYQQK
PGKQPKLLIYSAGNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQINELPYTF
GQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

シグナル配列（１－２０）、可変領域（２１－１２９）、定常領域（１３０－２３４）

[図11]

配列番号１１：抗ＣＤＨ６抗体重鎖のアミノ酸配列

MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQA
PGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARG
VYGGFAGGYFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD
KRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

シグナル配列（１－１９）、可変領域（２０－１４１）、定常領域（１４２－４７１）

[図12]

配列番号１２：抗ＣＤＨ６抗体軽鎖のアミノ酸配列

MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQK
PGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFG
QGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

シグナル配列（１－２０）、可変領域（２１－１２８）、定常領域（１２９－２３３）

[図13]

配列番号１３：ｈＨ１のアミノ酸配列

MKHLWFFLLLVAAPRWVLSQVQLVESGGGVVQPGRSLRLSCAASGFTFSDYGMIWVRQA
PGKGLEWVASISSSSSYIYYADSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARR
YYGFNYPFDYWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKR
VESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT
ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

シグナル配列（１－１９）、可変領域（２０－１３９）、定常領域（１４０－４６６）

[図14]

配列番号１４：ｈＨ２のアミノ酸配列

MKHLWFFLLLVAAPRWVLSEVQLVESGGGVVQPGRSLRLSCAASGFTFSDYGMIWVRQA
PGKGLEWVASISSSSSYIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARR
YYGFNYPFDYWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKR
VESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT
ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

シグナル配列（１－１９）、可変領域（２０－１３９）、定常領域（１４０－４６６）

[図15]

配列番号１５：ｈＬ２のアミノ酸配列

MVLQTQVFISLLLWISGAYGAIQLTQSPSSLSASVGQRVTITCGASKSVRTYMHWYQQK
PGKAPKLLIYSASNLEAGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEPPYTF
GQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

シグナル配列（１－２０）、可変領域（２１－１２７）、定常領域（１２８－２３４）

[図16]

配列番号１６：ｈＬ３のアミノ酸配列

MVLQTQVFISLLLWISGAYGDTQLTQSPSSLSASVGQRVTITCGASKSVRTYMHWYQQK
PGKQPKLLIYSASNLEAGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEPPYTF
GQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

シグナル配列（１－２０）、可変領域（２１－１２７）、定常領域（１２８－２３４）

[図17]

配列番号１７：ｈＬ４のアミノ酸配列

MVLQTQVFISLLLWISGAYGDTVLTQSPDSLAVSLGQRATINCGASKSVRTYMHWYQQK
PGQQPKLLIYSASNLEAGVPSRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEPPYTF
GQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

シグナル配列（１－２０）、可変領域（２１－１２７）、定常領域（１２８－２３４）

[図18]

配列番号１８：Ｄ１３　ＣＤＲＨ１
GFTFSDYGMI

配列番号１９：Ｄ１３　ＣＤＲＨ２
SISSSSSYIY

配列番号２０：Ｄ１３　ＣＤＲＨ３
RYYGFNYPFDY

配列番号２１：Ｄ１３　ＣＤＲＬ１
GASKSVRTYMH

配列番号２２：Ｄ１３　ＣＤＲＬ２
SASNLEA

配列番号２３：Ｄ１３　ＣＤＲＬ３
QQSNEPPYT

[図19]

配列番号２４：ＯＳＥ－１７２抗体重鎖（ＯＳＥ－１７２＿ｈＧ４Ｐｒｏ）のアミノ酸配列

MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGESLRISCKASGYSFTSYWVHWVRQM
PGKGLEWMGNIDPSDSDTHYSPSFQGHVTLSVDKSISTAYLQLSSLKASDTAMYYCVRG
GTGTLAYFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKR
VESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT
ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK*

配列番号２５：ＯＳＥ－１７２抗体軽鎖（ＯＳＥ－１７２＿ｈＫ）のアミノ酸配列

MVLQTQVFISLLLWISGAYGDVVMTQSPLSLPVTLGQPASISCRSSQSLVHSYGNTYLY
WFQQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGTH
VPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN
ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
GEC*

[図20]

配列番号２６：ＫＷＡＲ２３抗体重鎖（ＫＷＡＲ２３__ｈＧ４Ｐｒｏ）のアミノ酸配列

MKHLWFFLLLVAAPRWVLSEVQLQQSGAELVKPGASVKLSCTASGFNIKDYYIHWVQQR
TEQGLEWIGRIDPEDGETKYAPKFQDKATITADTSSNTAYLHLSSLTSEDTAVYYCARW
GAYWGQGTLVTVSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGP
PCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ
PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK*

配列番号２７：ＫＷＡＲ２３抗体軽鎖（ＫＷＡＲ２３__ｈＫ）のアミノ酸配列

MVLQTQVFISLLLWISGAYGQIVLTQSPAIMSASPGEKVTLTCSASSSVSSSYLYWYQQ
KPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCHQWSSYPRT
FGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*

[図21]

配列番号２８：ＡＤＵ－１８０５抗体重鎖（ＡＤＵ－１８０５＿ｈＧ２）のアミノ酸配列

MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVVKPGASVKLSCKASGSTFTSYWMHWVKQA
PGQGLEWIGAIYPVNSDTTYNQKFKGKATLTVDKSASTAYMELSSLRSEDTAVYYCTRS
FYYSLDAAWFVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVD
KTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF
NWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEK
TISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

配列番号２９：ＡＤＵ－１８０５抗体軽鎖（ＡＤＵ－１８０５＿ｈＫ）のアミノ酸配列

MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCRASQDIGSRLNWLQQK
PGKAPKRLIYATSSLDSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQYASSPFTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*

[図22]

配列番号３０

抗マウスＳＩＲＰα抗体５Ｃ１２＿ ｍＩｇＧ１＿Ｄ２６５Ａの重鎖のアミノ酸配列

MKHLWFFLLLVAAPRWVLSEVQLVESGGGLVQPGGSLKLSCAASGFTFSNYDMAWVRQA
PTKGLEWVASISTRGGSSYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCARH
PGDYFDYWGQGVMVTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTW
NSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPR
DCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVAISKDDPEVQFSWFVDDV
EVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKG
RPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDT
DGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK*

配列番号３１

抗マウスＳＩＲＰα抗体５Ｃ１２＿ ｍＩｇＧ１＿Ｄ２６５Ａの軽鎖のアミノ酸配列

MVLQTQVFISLLLWISGAYGDTVLTQSPALAVSPGERVTISCRASESVSTLIHWYQQKP
GQQPKLLIYLTSHLESGVPARFSGSGSGTDFTLTIDPVEADDTATYYCQQSWTHPWTFG
GGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNG
VLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC*

[図23]

配列番号３２

抗ＰＤ－Ｌ１抗体ＹＷ２４３．５５Ｓ７０＿ｍＩｇＧ１の重鎖のアミノ酸配列


MKHLWFFLLLVAAPRWVLSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQA
PGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARR
HWPGGFDYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVT
WNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVP
RDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDD
VEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTK
GRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMD
TDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK*

配列番号３３


抗ＰＤ－Ｌ１抗体ＹＷ２４３．５５Ｓ７０＿ｍＩｇＧ１の軽鎖のアミノ酸配列

MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQK
PGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATF
GQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQN
GVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC*


[図24]


ATP
HMGB1
A
MTX
RLU
Concentration (μM)
B
化合物 (A)
C
D
HMGB1 (ng/mL)
N=3
** P<0.01
*** P<0.0001


[図25]


□Ctrl. IgG [N=3]
■anti-CARL [N=3]
*** P<0.0001
MFI
2400
2000
1600
1200
800
400
0
***
***
Medium
Medium + DMSO
MTX 1 μM
化合物 (A) 4 μM

[図26]




[図27]




Treatment of cells	Treatment of mice	CR (左)	CR (右)
MTX (陽性対照)	PBS	2/6	6/6
	αSIRPα	4/6	6/6
	αCD47	3/6	6/6
化合物 (A)	PBS	5/6	2/6
	αSIRPα	6/6	2/6
	αCD47	6/6	1/6
NCD (陰性対照)	PBS	1/6	6/6
	αSIRPα	1/6	6/6
	αCD47	1/6	6/6


[図28]


Number of IFNγ Spots
160
140
120
100
80
60
40
20
0
*
*
PBS
aSIRPα
aCD47
PBS
aSIRPα
aCD47
PBS
MTX (陽性対照)
化合物 (A)
NCD (陰性対照)
N=6
* P < 0.05


[図29]


A
CD4+Tcm
% of CD4T
100
80
60
40
20
0
***
***
PBS
MTX (p.c.)
PBS
化合物 (A)
PBS
NCD (n.c.)
B
CD8+Tcm
% of CD8T
100
80
60
40
20
0
***
***
PBS
MTX (p.c.)
PBS
化合物 (A)
PBS
NCD (n.c.)
N=6
*** P < 0.0005


[図30]


A
CD4+Tcm
% of CD4T
PBS
αSIRPα
αCD47
PBS
αSIRPα
αCD47
MTX (p.c.)
DXd
NCD
N=6
***
B
CD8+Tcm
% of CD8T
PBS
αSIRPα
αCD47
PBS
αSIRPα
αCD47
MTX (p.c.)
DXd
NCD
N=6
*
**
C
% of Whole cells
Other
CD8
CD4
PBS
αSIRPα αCD47
PBS
αSIRPα αCD47
MTX (p.c.)
化合物 (A)
PBS
NCD (n.c.)
N=6
*
Tcm : central memory T cells [CD44(+) CD62L(+)]
* P < 0.05

[図31]



A
HER2
ADCP (%)
N=3
No treatment
Control IgG
αSIRPα_2000
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_10
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_100
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_1000
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_10000
Control 抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_1000
Trastuzumab
+αSIRPα
B
TROP2
ADCP (%)
N=3
No treatment
Control IgG
αSIRPα_2000
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_10
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_100
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_1000
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_10000
Control 抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ_1000
αTROP2_10
αTROP2_100
αTROP2_1000
+αSIRPα
C
HER2
ADCP (%)
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ (1)
Control 抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ
aSIRPα Ab Conc. (ng/mL)
N=3
D
TROP2
ADCP (%)
抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ (2)
Control 抗体-薬物ｺﾝｼﾞｭｹﾞｰﾄ
aSIRPα Ab Conc. (ng/mL)
N=3

[図32]




Treatment	TGI % (d21)	CR mice
PBS	-	0/5
抗体-薬物コンジュゲート(1)	74	0/5
aPD-L1	4	0/5
aSIRPa	41	0/5
抗体-薬物コンジュゲート(1) +aPD-L1	75	0/5
抗体-薬物コンジュゲート(1) +aSIRPa	88	0/5
抗体-薬物コンジュゲート(1) +aPD-L1+aSIRPa	90	1/5

[図33]



Treatment	TGI %(d18)
PBS	-
抗体-薬物コンジュゲート(2)	31
aSIRPa	31
抗体-薬物コンジュゲート(2) +aSIRPa	58

[図34]



Treatment	TGI %(d18)
PBS	-
抗体-薬物コンジュゲート(3)	21
aSIRPa	-41
抗体-薬物コンジュゲート(3) +aSIRPa	46